Holm Eggemann1, Udo Altmann2, Serban-Dan Costa3, Atanas Ignatov3. 1. Department of Obstetrics and Gynaecology, Otto-von-Guericke University, G.-Hauptmann Strasse 35, 39108, Magdeburg, Germany. holm.eggemann@med.ovgu.de. 2. Clinical Tumour Registry Coordination, Justus Liebig University, Giessen, Germany. 3. Department of Obstetrics and Gynaecology, Otto-von-Guericke University, G.-Hauptmann Strasse 35, 39108, Magdeburg, Germany.
Abstract
BACKGROUND: Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC). PATIENTS AND METHODS: We performed a retrospective study of 2785 FBC and 257 MBC patients treated with hormonal therapy. RESULTS: The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively. The patients were divided into two groups according to the hormonal therapy used: TAM-treated and AI-treated. MBC was characterized by older age, advanced tumor stage, and higher rate of lymph node metastases, in comparison with FBC. Matching analysis was performed using six prognostic criteria: patient age, tumor stage, tumor grade, lymph node status, human epidermal growth factor receptor (HER2) status, and administration of chemotherapy. The female and male patients were matched 2:1. In this analysis, 316 women and 158 men treated with TAM, and 60 women and 30 men treated with AI, were included. The overall survival (OS) was estimated by the Kaplan-Meier method and was compared between FBC and MBC. TAM-treated FBC and MBC patients had similar 5-year OS, 85.1 and 89.2%, respectively (p = 0.972). Notably, FBC patients treated with AI had significantly greater 5-year OS (85.0%) in comparison with AI-treated MBC patients (5-year OS of 73.3%; p = 0.028). CONCLUSIONS: The OS of TAM-treated patients with MBC was similar to the OS of TAM-treated FBC patients, whereas AI treatment is associated with poorer survival of MBC patients.
BACKGROUND: Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC). PATIENTS AND METHODS: We performed a retrospective study of 2785 FBC and 257 MBCpatients treated with hormonal therapy. RESULTS: The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively. The patients were divided into two groups according to the hormonal therapy used: TAM-treated and AI-treated. MBC was characterized by older age, advanced tumor stage, and higher rate of lymph node metastases, in comparison with FBC. Matching analysis was performed using six prognostic criteria: patient age, tumor stage, tumor grade, lymph node status, humanepidermal growth factor receptor (HER2) status, and administration of chemotherapy. The female and male patients were matched 2:1. In this analysis, 316 women and 158 men treated with TAM, and 60 women and 30 men treated with AI, were included. The overall survival (OS) was estimated by the Kaplan-Meier method and was compared between FBC and MBC. TAM-treated FBC and MBCpatients had similar 5-year OS, 85.1 and 89.2%, respectively (p = 0.972). Notably, FBC patients treated with AI had significantly greater 5-year OS (85.0%) in comparison with AI-treated MBCpatients (5-year OS of 73.3%; p = 0.028). CONCLUSIONS: The OS of TAM-treated patients with MBC was similar to the OS of TAM-treated FBC patients, whereas AI treatment is associated with poorer survival of MBCpatients.
Entities:
Keywords:
Aromatase inhibitor; Male breast cancer; Tamoxifen
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Holm Eggemann; Tanja Ignatov; Elke Burger; Eva Johanna Kantelhardt; Franziska Fettke; Christoph Thomssen; Serban Dan Costa; Atanas Ignatov Journal: Endocr Relat Cancer Date: 2015-07-17 Impact factor: 5.678
Authors: Holm Eggemann; Atanas Ignatov; Bobbie J Smith; Udo Altmann; Gunter von Minckwitz; Freidrich W Röhl; Mark Jahn; Serban-Dan Costa Journal: Breast Cancer Res Treat Date: 2012-12-09 Impact factor: 4.872
Authors: Tessa De Vrieze; Nick Gebruers; Ines Nevelsteen; Wiebren A A Tjalma; Sarah Thomis; An De Groef; Lore Dams; Vincent Haenen; Nele Devoogdt Journal: Support Care Cancer Date: 2020-11-24 Impact factor: 3.603
Authors: Nick Gebruers; Melissa Camberlin; Fleur Theunissen; Wiebren Tjalma; Hanne Verbelen; Timia Van Soom; Eric van Breda Journal: Support Care Cancer Date: 2018-10-09 Impact factor: 3.603
Authors: Shai White-Gilbertson; Ping Lu; Christian M Jones; Stephanie Chiodini; Deborah Hurley; Arabinda Das; Joe R Delaney; James S Norris; Christina Voelkel-Johnson Journal: Cancer Med Date: 2020-03-05 Impact factor: 4.452